ClinConnect ClinConnect Logo
Search / Trial NCT03984084

Biological Classification of Mental Disorders

Launched by MAX-PLANCK-INSTITUTE OF PSYCHIATRY · Jun 11, 2019

Trial Information

Current as of September 08, 2025

Recruiting

Keywords

Biomarkers Translational Medical Research Psychiatry Research Domain Criteria (R Do C) Omics Neuroimaging Taxonomy

ClinConnect Summary

The BeCOME trial is studying different types of mental disorders, such as depression, anxiety, and stress-related conditions. The goal is to better understand these disorders by looking at how people respond to certain tasks and tests that mimic real-life situations, like dealing with stress or anticipating rewards. The researchers will gather detailed information from at least 1,000 participants with mental disorders and 500 individuals without any mental health issues. This will help them to classify mental disorders in a more scientific way based on biological data.

To be eligible for the study, participants must have a diagnosed mental disorder according to recognized medical guidelines, or they may be completely healthy with no mental health issues. Those interested can expect to undergo a screening visit followed by two days of various assessments, including tests on their brain activity and physical responses. It's important to note that certain individuals, such as those currently taking specific medications or with severe health issues, may not qualify for participation. This study aims to improve our understanding of mental health and could contribute to better treatments in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Presence of an affective, anxiety or stress-related mental disorder according to the criteria of DSM-IV or DSM-5 (Depressive disorders;Anxiety and obsessive-compulsive disorders: agoraphobia with and without panic disorder, panic disorder, social phobia, specific phobia, generalized anxiety disorder, obsessive compulsive disorder; Stress and trauma-associated mental disorders (e.g. posttraumatic stress disorder).
  • or no mental disorder
  • Exclusion Criteria:
  • Intake of any psychotropic medication/substance for a minimum of 2 months before study day 1.
  • Current illness in the field of organic mental disorders;
  • Affective disorders caused by a medical condition
  • Organic mental disorders (e.g. dementia)
  • Current disorders of schizophrenia;
  • Current eating disorder;
  • Mental retardation and profound developmental disorders;
  • Severe neurological or internal medical illness;
  • Posttraumatic or post-ischemic brain damage or elapsed cerebral hemorrhage;
  • Acute suicidality;
  • Pregnancy and postpartum period;
  • Magnetic resonance imaging contraindications (e.g. non-MR compatible metal implants including cardiac pacemakers, claustrophobia);
  • Myopia \<-6 D, which cannot be compensated by contact lenses or MR compatible glasses (Cambridge Research Systems, Rochester, UK);
  • Current substance abuse;
  • Current or past substance dependence;
  • Risky alcohol consumption, screened with the Alcohol Use Disorder Identification Test - Consumption questions (AUDIT-C) and defined as score of ≥5 in males and of ≥4 in females.

About Max Planck Institute Of Psychiatry

The Max Planck Institute of Psychiatry is a leading research institution dedicated to advancing the understanding of mental health disorders through innovative scientific inquiry. Located in Munich, Germany, the Institute combines interdisciplinary approaches to explore the biological, psychological, and environmental factors influencing psychiatric conditions. By collaborating with clinicians and researchers globally, the Institute aims to translate fundamental research findings into effective therapeutic strategies. With a commitment to excellence in research and clinical application, the Max Planck Institute of Psychiatry plays a pivotal role in shaping the future of mental health care and improving patient outcomes.

Locations

Munich, Bavaria, Germany

Patients applied

0 patients applied

Trial Officials

Elisabeth B Binder, Prof. Dr. Dr.

Principal Investigator

Max-Planck-Institute of Psychiatry

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials